{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:18Z","timestamp":1787020158611,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2846-2","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T07:09:47Z","timestamp":1512544187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis"],"prefix":"10.1186","volume":"17","author":[{"given":"Mar\u00eda Fernanda","family":"Gonz\u00e1lez-Lara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Torres-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Cornejo-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Vel\u00e1zquez-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areli","family":"Martinez-Gamboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rangel-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Bobadilla-del-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Ponce-de-Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Sifuentes-Osornio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"2846_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.00029-06","volume":"20","author":"MA Pfaller","year":"2007","unstructured":"Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:1.","journal-title":"Clin Microbiol Rev"},{"key":"2846_CR2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1128\/JCM.00773-06","volume":"44","author":"AL Colombo","year":"2006","unstructured":"Colombo AL, Nucci M, Park BJ, Nouer SA, Arthington-Skaggs B, da Matta DA, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44:8.","journal-title":"J Clin Microbiol"},{"key":"2846_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pone.0059373","volume":"8","author":"M Nucci","year":"2013","unstructured":"Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One. 2013;8:3.","journal-title":"PLoS One"},{"key":"2846_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12281-011-0081-7","volume":"6","author":"J Sifuentes-Osornio","year":"2012","unstructured":"Sifuentes-Osornio J, Corzo-Leon DE, Ponce-de-Leon LA. Epidemiology of invasive fungal infections in Latin America. Curr Fungal Infect Rep. 2012;6:1.","journal-title":"Curr Fungal Infect Rep"},{"key":"2846_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jac\/dkm212","volume":"60","author":"MD Parkins","year":"2007","unstructured":"Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60:3.","journal-title":"J Antimicrob Chemother"},{"key":"2846_CR6","first-page":"9","volume":"66","author":"DN Shah","year":"2011","unstructured":"Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:9.","journal-title":"J Antimicrob Chemother"},{"key":"2846_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/JCM.03044-13","volume":"52","author":"AW Fothergill","year":"2014","unstructured":"Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clinical Microbiol. 2014;52:3.","journal-title":"J Clinical Microbiol"},{"key":"2846_CR8","first-page":"3","volume":"45","author":"MA Pfaller","year":"2007","unstructured":"Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol. 2007;45:3.","journal-title":"J Clin Microbiol"},{"key":"2846_CR9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/JCM.02517-10","volume":"49","author":"JF Peterson","year":"2011","unstructured":"Peterson JF, Pfaller MA, Diekema DJ, Rinaldi MG, Riebe KM, Ledeboer NA. Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp. J Clin Microbiol. 2011;49:5.","journal-title":"J Clin Microbiol"},{"key":"2846_CR10","first-page":"11","volume":"45","author":"MA Pfaller","year":"2007","unstructured":"Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol. 2007;45:11.","journal-title":"J Clin Microbiol"},{"key":"2846_CR11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:4.","journal-title":"Clin Infect Dis"},{"key":"2846_CR12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/CCM.0b013e31827e83af","volume":"41","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:2.","journal-title":"Crit Care Med"},{"key":"2846_CR13","doi-asserted-by":"crossref","unstructured":"DePestel DD, Eiland EH, 3rd, Lusardi K, Destache CJ, Mercier RC, McDaneld PM, et al. Assessing appropriateness of antimicrobial therapy: in the eye of the interpreter. Clin Infect Dis. 2014;59;Suppl 3:S154-61.","DOI":"10.1093\/cid\/ciu548"},{"key":"2846_CR14","first-page":"9","volume":"50","author":"MA Pfaller","year":"2012","unstructured":"Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of clinical and laboratory standards institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:9.","journal-title":"J Clin Microbiol"},{"key":"2846_CR15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.drup.2010.09.002","volume":"13","author":"MA Pfaller","year":"2010","unstructured":"Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Testing CSfAS. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13:6.","journal-title":"Drug Resist Updat"},{"key":"2846_CR16","first-page":"11","volume":"59","author":"A Espinel-Ingroff","year":"2015","unstructured":"Espinel-Ingroff A, Alvarez-Fernandez M, Canton E, Carver PL, Chen SC, Eschenauer G, et al. Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method. Antimicrob Agents Chemother. 2015;59:11.","journal-title":"Antimicrob Agents Chemother"},{"key":"2846_CR17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/QCO.0000000000000111","volume":"27","author":"MC Arendrup","year":"2014","unstructured":"Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis. 2014;27:6.","journal-title":"Curr Opin Infect Dis"},{"key":"2846_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01382-12","volume":"57","author":"KM Astvad","year":"2013","unstructured":"Astvad KM, Perlin DS, Johansen HK, Jensen RH, Arendrup MC. Evaluation of caspofungin susceptibility testing by the new Vitek 2 AST-YS06 yeast card using a unique collection of FKS wild-type and hot spot mutant isolates, including the five most common candida species. Antimicrob Agents Chemother. 2013;57:1.","journal-title":"Antimicrob Agents Chemother"},{"key":"2846_CR19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drup.2011.01.004","volume":"14","author":"MA Pfaller","year":"2011","unstructured":"Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug resistance updat. 2011;14:3.","journal-title":"Drug resistance updat"},{"key":"2846_CR20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cid\/civ1194","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the Management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:4.","journal-title":"Clin Infect Dis"},{"key":"2846_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s40506-015-0056-2","volume":"7","author":"N Nachimuthu","year":"2015","unstructured":"Nachimuthu N, Ostrosky-Zeichner L. Antifungal susceptibility testing: evolution, indications, and role in clinical practice. Curr Treat Options Infect Dis. 2015;7:3.","journal-title":"Curr Treat Options Infect Dis"},{"key":"2846_CR22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkq136","volume":"65","author":"DA Oxman","year":"2010","unstructured":"Oxman DA, Chow JK, Frendl G, Hadley S, Hershkovitz S, Ireland P, et al. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J Antimicrob Chemother. 2010;65:7.","journal-title":"J Antimicrob Chemother"},{"key":"2846_CR23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1469-0691.12004","volume":"19","author":"R Ben-Ami","year":"2013","unstructured":"Ben-Ami R, Rahav G, Elinav H, Kassis I, Shalit I, Gottesman T, et al. Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel. Clin Microbiol Infect. 2013;19:8.","journal-title":"Clin Microbiol Infect"},{"key":"2846_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jac\/dks204","volume":"67","author":"SA Grim","year":"2012","unstructured":"Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother. 2012;67:3.","journal-title":"J Antimicrob Chemother"},{"key":"2846_CR25","first-page":"2","volume":"64","author":"SY Chen","year":"2009","unstructured":"Chen SY, Tsai CL, Lin CH, Lee CC, Chiang WC, Wang JL, et al. Impact of liver cirrhosis on mortality in patients with community-acquired bacteremia. Diagn Microbiol Infect Dis. 2009;64:2.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2846_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhep.2014.03.021","volume":"61","author":"M Bartoletti","year":"2014","unstructured":"Bartoletti M, Giannella M, Caraceni P, Domenicali M, Ambretti S, Tedeschi S, et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. J Hepatol. 2014;61:1.","journal-title":"J Hepatol"},{"key":"2846_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cgh.2011.02.031","volume":"9","author":"AR Bonnel","year":"2011","unstructured":"Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:9.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2846_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/liv.12021","volume":"33","author":"P Bellot","year":"2013","unstructured":"Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liv Int. 2013;33:1.","journal-title":"Liv Int"},{"key":"2846_CR29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/320757","volume":"32","author":"O Uzun","year":"2001","unstructured":"Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis. 2001;32:12.","journal-title":"Clin Infect Dis"},{"key":"2846_CR30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(98)00030-8","volume":"104","author":"EJ Anaissie","year":"1998","unstructured":"Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med. 1998;104:3.","journal-title":"Am J Med"},{"key":"2846_CR31","first-page":"4","volume":"21","author":"JH Rex","year":"1995","unstructured":"Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis. 1995;21:4.","journal-title":"Clin Infect Dis"},{"key":"2846_CR32","first-page":"3","volume":"51","author":"M Nucci","year":"2010","unstructured":"Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis. 2010;51:3.","journal-title":"Clin Infect Dis"},{"key":"2846_CR33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/cid\/cis021","volume":"54","author":"DR Andes","year":"2012","unstructured":"Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:8.","journal-title":"Clin Infect Dis"},{"key":"2846_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/504810","volume":"43","author":"KW Garey","year":"2006","unstructured":"Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:1.","journal-title":"Clin Infect Dis"},{"key":"2846_CR35","first-page":"12","volume":"54","author":"M Kollef","year":"2012","unstructured":"Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:12.","journal-title":"Clin Infect Dis"},{"key":"2846_CR36","first-page":"4","volume":"48","author":"MA Pfaller","year":"2010","unstructured":"Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48:4.","journal-title":"J Clin Microbiol"},{"key":"2846_CR37","first-page":"8","volume":"51","author":"MA Pfaller","year":"2013","unstructured":"Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51:8.","journal-title":"J Clin Microbiol"},{"key":"2846_CR38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1128\/AAC.02670-14","volume":"58","author":"LJ Marcos-Zambrano","year":"2014","unstructured":"Marcos-Zambrano LJ, Escribano P, Sanchez C, Munoz P, Bouza E, Guinea J. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother. 2014;58:8.","journal-title":"Antimicrob Agents Chemother"},{"key":"2846_CR39","first-page":"2","volume":"10","author":"EJ Won","year":"2015","unstructured":"Won EJ, Shin JH, Choi MJ, Lee WG, Park YJ, Uh Y, et al. Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea: application of new antifungal breakpoints and relationship to antifungal usage. PLoS One. 2015;10:2.","journal-title":"PLoS One"},{"key":"2846_CR40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/AAC.00285-15","volume":"59","author":"B Posteraro","year":"2015","unstructured":"Posteraro B, Spanu T, Fiori B, De Maio F, De Carolis E, Giaquinto A, et al. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. Antimicrob Agents Chemother. 2015;59:7.","journal-title":"Antimicrob Agents Chemother"},{"key":"2846_CR41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ofid\/ofv133.637","volume":"2","author":"S Vallabhaneni","year":"2015","unstructured":"Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG, et al. Epidemiology and risk factors for Echinocandin nonsusceptible Candida Glabrata bloodstream infections: data from a large multisite population-based Candidemia surveillance program, 2008-2014. Open Forum Infect Dis. 2015;2:4.","journal-title":"Open Forum Infect Dis"},{"key":"2846_CR42","first-page":"6","volume":"52","author":"MA Pfaller","year":"2014","unstructured":"Pfaller MA, Diekema DJ, Procop GW, Wiederhold NP. Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole. J Clin Microbiol. 2014;52:6.","journal-title":"J Clin Microbiol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2846-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T07:10:18Z","timestamp":1512544218000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2846-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2846"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2846-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"753"}}